Liberty Capital Management Inc. reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 46.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,360 shares of the biopharmaceutical company’s stock after selling 1,180 shares during the quarter. Liberty Capital Management Inc.’s holdings in Gilead Sciences were worth $107,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently added to or reduced their stakes in the company. FMR LLC increased its position in Gilead Sciences by 1.1% in the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after buying an additional 258,005 shares during the last quarter. Macquarie Group Ltd. grew its position in shares of Gilead Sciences by 26.6% in the third quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock valued at $38,836,000 after purchasing an additional 100,741 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after purchasing an additional 2,148,697 shares in the last quarter. Northern Trust Corp grew its position in shares of Gilead Sciences by 0.7% in the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after purchasing an additional 116,780 shares in the last quarter. Finally, Toronto Dominion Bank grew its position in shares of Gilead Sciences by 19.0% in the second quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock valued at $33,445,000 after purchasing an additional 75,364 shares in the last quarter. 76.47% of the stock is owned by institutional investors and hedge funds.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $80.70 on Friday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.48 and a current ratio of 3.55. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $89.54. The stock has a market capitalization of $105,415.91, a PE ratio of 23.19, a price-to-earnings-growth ratio of -1.85 and a beta of 1.22.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same quarter in the previous year, the company posted $2.70 earnings per share. The company’s revenue was down 18.7% compared to the same quarter last year. sell-side analysts forecast that Gilead Sciences, Inc. will post 6.24 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be paid a dividend of $0.57 per share. The ex-dividend date is Thursday, March 15th. This represents a $2.28 annualized dividend and a yield of 2.83%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is 59.77%.
In other Gilead Sciences news, Director Gayle E. Wilson sold 60,000 shares of Gilead Sciences stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $77.92, for a total transaction of $4,675,200.00. Following the completion of the sale, the director now owns 182,258 shares of the company’s stock, valued at $14,201,543.36. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $74.64, for a total value of $1,119,600.00. Following the sale, the executive vice president now directly owns 70,988 shares of the company’s stock, valued at approximately $5,298,544.32. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 418,333 shares of company stock valued at $32,742,108. Corporate insiders own 1.30% of the company’s stock.
GILD has been the subject of several recent research reports. Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price target for the company. in a research report on Wednesday, January 17th. BMO Capital Markets reduced their price target on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a research report on Friday, October 27th. Credit Suisse Group reiterated a “buy” rating and issued a $82.00 price target on shares of Gilead Sciences in a research report on Thursday, December 7th. Maxim Group set a $94.00 price target on Gilead Sciences and gave the company a “buy” rating in a research report on Monday, December 11th. Finally, Zacks Investment Research cut Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $87.04.
TRADEMARK VIOLATION NOTICE: “Liberty Capital Management Inc. Sells 1,180 Shares of Gilead Sciences, Inc. (GILD)” was posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.thelincolnianonline.com/2018/02/18/liberty-capital-management-inc-sells-1180-shares-of-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.